◎ Sugi Atlas

Atlas / Drug / Bimagrumab

Bimagrumab

drug
On this page

Also known as BYM-338BYM338O81t794r34

Summary

Bimagrumab (CHEMBL3137353) is a phase-3 clinical-stage antibody targeting ACVR2A and ACVR2B; indicated across 6 conditions including inclusion body myositis and chronic obstructive pulmonary disease.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Antibody
  • Targets: 2 (ACVR2A, ACVR2B)
  • Indications: 6 conditions
  • Clinical trials: 16

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL3137353
NameBimagrumab
TypeAntibody
Max phase3

Also known as: Bimagrumab, BYM-338, BYM338, O81t794r34, BIMAGRUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
ACVR2Aactivin A receptor type 2ABinding9.361.4%P27037
ACVR2Bactivin A receptor type 2BBinding11.760.4%Q13705

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 2 target gene(s): ACVR2A, ACVR2B.

Top Reactome pathways

9 total, by targets touching each:

PathwayTargetsGenes
Signaling by NODAL2ACVR2A, ACVR2B
Developmental Biology2ACVR2A, ACVR2B
Regulation of signaling by NODAL2ACVR2A, ACVR2B
Signaling by Activin2ACVR2A, ACVR2B
Signal Transduction2ACVR2A, ACVR2B
Signaling by BMP2ACVR2A, ACVR2B
Signaling by TGFB family members2ACVR2A, ACVR2B
Signaling by TGFBR31ACVR2A
TGFBR3 regulates activin signaling1ACVR2A

Dominant GO biological processes

GO termTargets
gastrulation with mouth forming second2
cell surface receptor protein serine/threonine kinase signaling pathway2
determination of left/right symmetry2
pattern specification process2
mesoderm development2
anterior/posterior pattern specification2
positive regulation of bone mineralization2
BMP signaling pathway2
activin receptor signaling pathway2
positive regulation of activin receptor signaling pathway2
odontogenesis of dentin-containing tooth2
positive regulation of osteoblast differentiation2
cellular response to growth factor stimulus2
protein phosphorylation2
regulation of signal transduction2

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
inclusion body myositis3MONDO:0007827EFO:0007323
chronic obstructive pulmonary disease2MONDO:0005002EFO:0000341
muscular atrophy2MONDO:0004323EFO:0009851
type 2 diabetes mellitus2MONDO:0005148MONDO:0005148

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 16.

Phase distribution

PhaseTrials
PHASE212
PHASE2/PHASE32
PHASE31
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01925209PHASE2/PHASE3COMPLETEDEfficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
NCT02250443PHASE2/PHASE3COMPLETEDStudy of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
NCT02573467PHASE3COMPLETEDAn Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
NCT05933499PHASE2RECRUITINGEffect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity
NCT06643728PHASE2ACTIVE_NOT_RECRUITINGA Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
NCT01423110PHASE2COMPLETEDEfficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
NCT01601600PHASE2COMPLETEDA Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults
NCT01669174PHASE2COMPLETEDBYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
NCT01868685PHASE2WITHDRAWNStudy of Muscle Effects of BYM338 in Mechanically Ventilated Patients
NCT02152761PHASE2COMPLETEDStudy of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
NCT02333331PHASE2COMPLETEDDose Range Finding Study of Bimagrumab in Sarcopenia
NCT02468674PHASE2COMPLETEDA 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study
NCT03005288PHASE2COMPLETEDSafety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
NCT05616013PHASE2COMPLETEDSafety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
NCT06901349PHASE2WITHDRAWNA Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
NCT06890611PHASE1COMPLETEDA Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

64 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
AxitinibChEMBL + PubChemPhase 4 (approved)ACVR2A, ACVR2B
PazopanibChEMBL + PubChemPhase 4 (approved)ACVR2A, ACVR2B
DASATINIBChEMBLPhase 4 (approved)ACVR2A, ACVR2B
ALVOCIDIBChEMBLPhase 3ACVR2A, ACVR2B
LESTAURTINIBChEMBLPhase 3ACVR2A, ACVR2B
AbemaciclibPubChemApprovedACVR2A, ACVR2B
AcalabrutinibPubChemApprovedACVR2A, ACVR2B
AfatinibPubChemApprovedACVR2A, ACVR2B
BosutinibPubChemApprovedACVR2A, ACVR2B
CrizotinibPubChemApprovedACVR2A, ACVR2B
ErlotinibPubChemApprovedACVR2A, ACVR2B
FedratinibPubChemApprovedACVR2A, ACVR2B
GefitinibPubChemApprovedACVR2A, ACVR2B
ImatinibPubChemApprovedACVR2A, ACVR2B
LapatinibPubChemApprovedACVR2A, ACVR2B
MidostaurinPubChemApprovedACVR2A, ACVR2B
NeratinibPubChemApprovedACVR2A, ACVR2B
NilotinibPubChemApprovedACVR2A, ACVR2B
QuizartinibPubChemApprovedACVR2A, ACVR2B
RuxolitinibPubChemApprovedACVR2A, ACVR2B
SelumetinibPubChemApprovedACVR2A, ACVR2B
SorafenibPubChemApprovedACVR2A, ACVR2B
SunitinibPubChemApprovedACVR2A, ACVR2B
TofacitinibPubChemApprovedACVR2A, ACVR2B
VandetanibPubChemApprovedACVR2A, ACVR2B
SARACATINIBChEMBLPhase 3ACVR2B
TG100-801ChEMBLPhase 2ACVR2B
VX-702ChEMBLPhase 2ACVR2B
AlectinibPubChemApprovedACVR2B
BaricitinibPubChemApprovedACVR2B
BinimetinibPubChemApprovedACVR2B
CabozantinibPubChemApprovedACVR2B
CapivasertibPubChemApprovedACVR2B
CapmatinibPubChemApprovedACVR2B
CeritinibPubChemApprovedACVR2B
CobimetinibPubChemApprovedACVR2B
DabrafenibPubChemApprovedACVR2B
dacomitinibPubChemApprovedACVR2B
EncorafenibPubChemApprovedACVR2B
EntrectinibPubChemApprovedACVR2B
EverolimusPubChemApprovedACVR2B
FostamatinibPubChemApprovedACVR2B
GilteritinibPubChemApprovedACVR2B
IbrutinibPubChemApprovedACVR2B
IdelalisibPubChemApprovedACVR2B
LenvatinibPubChemApprovedACVR2B
mirdametinibPubChemApprovedACVR2B
MomelotinibPubChemApprovedACVR2B
OsimertinibPubChemApprovedACVR2B
PacritinibPubChemApprovedACVR2B
PalbociclibPubChemApprovedACVR2B
PexidartinibPubChemApprovedACVR2B
PonatinibPubChemApprovedACVR2B
regorafenibPubChemApprovedACVR2B
RibociclibPubChemApprovedACVR2B
SirolimusPubChemApprovedACVR2B
TemsirolimusPubChemApprovedACVR2B
TepotinibPubChemApprovedACVR2B
TirbanibulinPubChemApprovedACVR2B
TivozanibPubChemApprovedACVR2B

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot